title: [Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer].
abstract: BACKGROUND
  The aim of this study was to determine the efficacy and safety of docetaxel-based systemic chemotherapy in elderly patients with castration-resistant prostate cancer (CRPC).
  
  
  METHODS
  We retrospectively reviewed the clinical records of 36 patients with CRPC who were treated with docetaxel-based systemic chemotherapy at a single institution between May 2005 and April 2010. After screening, 30 patients met the eligibility criteria, and were included. Patients were placed into 2 groups: group 1 consisted of 9 patients aged <70 years, and group 2 consisted of 21 patients aged ≥70 years. The treatment consisted of prednisolone (5mg) twice daily and docetaxel (75 mg/m(2)) once every 3 weeks.
  
  
  RESULTS
  The median age was 72 years, and the median performance status was 0. The median baseline prostate specific antigen (PSA) was 33.8 ng/mL. The mean number of docetaxel chemotherapy cycles was 5.8. The PSA response rate was 48.2%, and the measurable disease response rate was 15.0%, and these rates did not differ between the two groups. The median time to PSA progression and median overall survival were 6 and 9 months, respectively. Five patients experienced grade 3 or higher neutropenia. The drug-related toxicity was not different between the two groups.
  
  
  CONCLUSIONS
  The response of elderly CRPC patients with good performance status to docetaxel-based systemic chemotherapy was similar to that of younger patients. Docetaxel-based systemic chemotherapy is generally tolerated in elderly patients with good performance status.
authors.affiliation: Servicio de Urología, Escuela Universitaria de Medicina y Hospital de Wonkwan, Instituto de Wonkwang Ciencia Médica, Iksan, Corea. sc.park@wonkwang.ac.kr
authors.forename: S C H
authors.initials: SC
authors.lastname: Park
authors.forename: L J
authors.initials: LJ
authors.lastname: Whan
authors.forename: R J
authors.initials: RJ
authors.lastname: Sik
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D044466:Asian People; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D043823:Taxoids / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel